

AIDS ACTION BALTIMORE, INC.

14 EAST EAGER STREET, BALTIMORE, MARYLAND 21202 (410) 837-2437 FAX (410) 837-2438
baltoaids@aol.com www.aidsactionbaltimore.org

ANNUAL REPORT 2019

AIDS Action Baltimore, Inc (AAB) is a non-profit, tax-exempt corporation under Section 501 (c)(3) of the Internal Revenue Code. AAB is governed by a seven member Board of Directors which is elected annually.

AIDS Action Baltimore, Inc. (AAB) is dedicated to providing patient services for all people in Baltimore City regardless of race, religion, age, disabilities, sexual orientation, gender or non-confirming gender, including emergency financial assistance, HIV education, testing assistance, navigation support for healthcare linkage, retention in care, medication adherence and access support, HIV prevention services, including outreach efforts and pre-exposure prophylaxis (PrEP) medication access.

AAB also administers HIV prevention programs for transgender people and MSM that promote HIV testing, help people get linked to care and treatment, and remain in treatment. AAB's new program New Horizons, is boosting empowerment and breaking the bonds of homophobia, racism, and stigma in same gender-loving (SGL) African-American men in Baltimore City.

AAB advocates for research, treatment and support services for people with hepatitis C virus (HCV). Many people are co-infected with both HIV and HCV. We also advocate for more efficient and more effective treatment services and research programs for people with HIV and HCV as well as fair pricing for newly approved drugs and limited price increases for HIV and HCV drugs.

AAB advocates for more effective treatment and research programs for HIV and HCV. AAB representatives work directly with officials of the Food and Drug Administration (FDA), and the National Institutes of Health (NIH), including NIAID's AIDS Clinical Trials Group (ACTG), the Johns Hopkins University AIDS Service, the Maryland State Infectious Disease and Environmental Health Administration, and all leading HIV and HCV pharmaceutical companies in conjunction with many national community organizations.

AAB also provides research and treatment information on our web site and at Town Hall Meetings to assist people with HIV and their families, advocates and care providers with essential information on the latest in prevention, research and treatment news.
(www.aidsactionbaltimore.org)

AAB provides all these services with four full-time employees, and our committed volunteers. AAB's administrative expenses for 2019 totaled only 6.1% of total revenues.

2019 Contributing Organizations: Baltimore City Health Department, Broadway Cares/Equity Fights AIDS, Brother Help Thyself, Gilead, Johnson & Johnson Healthcare Systems, Nordstrom and the M-A-C AIDS Fund, 12 Days of Christmas, and ViiV.

PATIENT SERVICES INDIVIDUAL HIV/AIDS ASSISTANCE PROGRAMS

AAB manages an HIV Emergency Financial Assistance Fund which provides immediate assistance to people with HIV who are experiencing a financial crisis as a result of HIV infection. Money is provided for housing and utilities, medical care or other non-reimbursable medical services.

Patients may apply to AAB personally or by referral. The application process is simple and easy, designed to be tailored to individual needs and individual circumstances. Applications are normally acted upon and the funds provided within days of submission.

HIV/AIDS SERVICES ORGANIZATIONS ASSISTANCE PROGRAM

Over the years, we have provided funding for the emergency assistance to patients, hospitals and community based organizations serving the Baltimore HIV/AIDS community. AAB has contributed over \$75,000 to Johns Hopkins Hospital HIV Patient Emergency Fund (B. Frank Polk Fund). AAB has provided emergency assistance funding to the University of Maryland Hospital, contributing over \$22,000 for Pediatric and Adolescent HIV/AIDS patient service programs.

AAB has also provided seed money and emergency assistance over the years to organizations such as Chase-Brexton Health Services, Inc., Moveable Feast, Sisters Together and Reaching and AIDS Interfaith Residential Services.

410-837-AIDS HELPLINE

AAB provides a Peer Counseling Program for people at all stages of HIV infection. This program is particularly useful for people who have recently tested positive for HIV or are newly diagnosed with AIDS who need basic information on available services and direction on how to tackle the maze of government entitlement programs. Sometimes the only support necessary is a friendly ear and some guidance. For those times, peer counseling is a phone call away. For a referral on virtually any HIV related problem or concern, the AAB Helpline is available - Monday through Friday from 9 am to 5 pm.

DROP-IN CENTER AND AIDS LIBRARY

The AAB office on Eager Street in the Mount Vernon area of Baltimore City doubles as a convenient "Drop-In Center" for anyone interested in learning more about AAB's programs and services, and taking a proactive role in their healthcare.

AAB PUBLICATIONS

AAB has a unique publications program designed to provide essential information to people with HIV, their families, advocates and care providers.

AAB provides online information from research conferences and national newsletters. Complex medical issues are covered by community experts and discussed in laymen's terms. We provide a compilation of articles from the best community treatment writers across the country on topics such as PrEP, new antiviral drugs, side effects, HIV and Aging, AIDS related cancers, neurological complications, Women and HIV as well as exciting new HIV "Cure" research and HCV treatment paradigm changing research information and COVID-19 Advocacy.

HIV COMMUNITY FORUMS

AAB conducts free community forums for people with HIV, their care givers and advocates, and people interested in PrEP in an effort to disseminate much needed treatment and prevention information from scientific conferences and meetings. We have conducted HIV forums since 1994. We conduct our forums throughout the community in partnership with other local AIDS service organizations in a continuing effort to outreach to all affected communities.

CLINICAL RESEARCH ADVOCACY PROGRAM

Since its founding in 1987, AAB has been deeply involved in the conduct of clinical research in HIV. The ultimate cure for HIV will only be found through research. AAB works to make HIV research more compassionate, safe, relevant to clinical practice, and more broadly inclusive of all people with HIV.

AAB's program has two goals:

The first is to expedite ethical drug development and make new drugs available to the people that need them the most as quickly and safely as possible. The second is to help educate the affected community in the latest medical and research information in an effort to empower people with HIV to discuss their medical care with their health providers.

To achieve our goals, AAB works with a variety of institutions, governmental agencies, and the pharmaceutical industry. AAB works with the Maryland Department of Health Infectious Diseases Bureau, the Baltimore City Health Department, the FDA, the National Institutes of Health (NIH), and a variety of national research advocacy groups. AAB Executive Director, Lynda Dee, has been a member of the NIH's Office of AIDS Research Clinical Trials Review Panel and the NIH's AIDS Clinical Trial Group Executive Committee and Community Constituency Group.

Ms. Dee is a national leader in drug development and treatment advocacy and access issues. She was a co-founder of AIDS Treatment Activists Coalition, and is a member of the National PrEP Access Coalition, co-chair of the Martin Delaney Collaboratory (MDC) DARE cure research CAB and the amfAR Cure Institute CAB, former co-chair of the MDC CARE CAB, and former co-chair and current member of the Fair Pricing Coalition. Ms. Dee has worked with the FDA, many NIH Institutes and every HIV drug manufacturer on their drug development and access programs. Ms. Dee has also been a member of the Executive Committee of the Forum for Collaborative HIV Research, which brings together experts in cutting edge areas of HIV research. Ms. Dee was a member of the Community Liaison Sub-Committee for the 5th through the 9th Conferences on Retroviruses and Opportunistic Infections. Ms. Dee continues to exert pressure on government and industry to study real life strategies for the use of new HIV drugs as well as their long-term side effects. She continues to advocate with Congress and drug companies to ensure drug safety as well as expedited and ethical development of new HIV drugs. Ms. Dee also serves locally on the Maryland AIDS Drug Assistance Program (ADAP) Advisory Board. ADAP provides lifesaving drugs to Maryland's working poor.

TREATMENT SERVICES ADVOCACY PROGRAM

AAB has taken a leadership role in ensuring that the law in Maryland regarding HIV testing requirements was streamlined in order to remove HIV testing barriers for people who want to be tested. Ms. Dee was a member of the former AIDS Administration Working Group mandated by the Maryland legislature in this regard. This is vitally important as in the latest Centers for Disease Control (CDC) data reported in 2018, Maryland was ranked 6th among U.S. states and territories in adult/adolescent HIV diagnosis rates (per 100,000) in 2018. At year-end 2017, CDC estimates that 1,003,782 persons in the United States were living with diagnosed HIV infection. At the end of 2018, there were 31,559 people aged 13+ living with diagnosed HIV infection. It is estimated that 11.6% of those people living with HIV in Maryland in 2017 were undiagnosed.

AAB is a leading member of the national Fair Pricing Coalition (FPC), working with the National Association of State AIDS Directors (NASTAD) and the AIDS Crisis Task Force (ACTF) to pressure “big pharma” to price new drugs reasonably and to limit drug price increases. The FPC and ACTF have forced drug companies to provide additional rebates to all national ADAP programs. The FPC has also pressured industry to initiate co-pay reimbursement programs for people with private insurance and free patient assistance programs (PAPs) for people with no healthcare coverage. Every major HIV drug manufacturer has agreed to PAPs and co-pay reimbursement programs as a result of the efforts of Ms. Dee and her dedicated FPC colleagues.

AAB is also working with many national advocates to ensure that we maintain currently covered HIV services and that the inclusion of all classes of antiviral drugs remain on new drug formularies.

BOARD OF DIRECTORS

Merle McCann, M.D. - Chairman
3704 N. Charles Street, #606
Baltimore, MD 21218

Thomas Holden
3626 Yolando Road
Baltimore, MD 21218

Michael Aquino
3424 Woodberry Avenue
Baltimore, MD 21211

Mark McMullen
3505 Newland Road
Baltimore, MD 21218

Jake Boone
235 West Lafayette
Baltimore, MD 21217

Cameron Wolf, Ph.D.
8706 Granite Lane
Laurel, MD 20708

Lynda Dee
3928 Cloverhill Road
Baltimore, MD 21218

OFFICERS

Lynda Dee
Executive Director

Jeffrey Grabelle
Chief Operating Officer

Jake Boone
Secretary

Thomas Holden
Treasurer

2019 EVENTS

January

Nominations for Board of Directors
ViiV Capacity Building and Sustainability Planning Workshop
T.E.A. Time, PrEP UP and New Horizons Meetings

February

Election of Board of Directors
Brother Help Thyself Grant Award Ceremony
Combined Charity Campaigns Acceptance
BCHD IMPACT Collaborative Meeting

March

MD State Combined Charity Campaign Acceptance
26th Conference on Retroviruses & Opportunistic Infections
CDC Prevention Conference
PrEP Town Hall, T.E.A. Time, PrEP UP and New Horizons Meetings

April

National Transgender HIV Testing Day and Health Awareness Week
DARE CAB Meeting
T.E.A. Time, PrEP UP and New Horizons Meetings

May

Direct Mail Drive
BCHD IMPACT Community Dinner
T.E.A. Time, PrEP UP and New Horizons Meetings

June

Gay Pride Parade and Festival
AIDSWALK
National HIV Testing Day
History of the AIDS Movement Town Hall
PrEP Town Hall, T.E.A. Time, PrEP UP and New Horizons Meetings

July

23rd International AIDS Conference
T.E.A. Time, PrEP UP and New Horizons Meetings

August

HIV CAB Meeting
Southern Decadence
LGBTQ Day at the Maryland Zoo
T.E.A. Time, PrEP UP and New Horizons Meetings

September

T3 at Cedarcroft Benefit
US Conference on AIDS
REACH Conference
PrEP Town Hall, T.E.A. Time, PrEP UP and New Horizons Meetings

October

Baltimore Black Pride Celebration
CFAR Investigators Symposium
OAR Meeting
T.E.A. Time, PrEP UP and New Horizons Meetings

November

Transgender Day of Remembrance
ViiV Healthcare 21th Annual Community Summit
Direct Mail Campaign
TRANScending Barriers Town Hall, T.E.A. Time, PrEP UP and New Horizons Meetings

December

World AIDS Day Celebration of Life
12 Days Of Christmas Benefit
DARE Meeting
Christmas Outreach
T.E.A. Time, PrEP UP and New Horizons Meetings

INDEPENDENT AUDITOR'S REPORT

To The Board of Directors, AIDS Action Baltimore, Inc.

We have audited the accompanying financial statements of AIDS Action Baltimore, Inc. (a nonprofit organization) which comprise the statement of financial position as of December 31, 2019 and 2018, and the related statements of activities, functional expenses and cash flows for the years then ended, and the related notes to the financial statements.

Management's Responsibility for the Financial Statements

The Organization's management is responsible for the preparation and fair representation of these financial statements in accordance with accounting principles generally accepted in the United States of America; this includes design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free from material misstatement, whether due to fraud or error.

Auditor's Responsibility

Our responsibility is to express an opinion on these financial statements based on our audit. We conducted our audit in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditor's judgement, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity's preparation and fair representation of the financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity's internal control. Accordingly, we express no such opinion. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluating the overall financial statement presentation.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Opinion

In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of AIDS Action Baltimore, Inc. as of December 31, 2019 and 2018, and the changes in its net assets and its cash flows for the years then ended in conformity with accounting principles generally accepted in the United States of America.

Friedman and Associates, P.A.,
Certified Public Accountants and Business Advisors
Baltimore, Maryland April 27, 2020

The following financial information is excerpted from the Auditor's Report. A complete copy of the Auditor's Report and Accompanying Notes, and/or current financial statement is available upon request by contacting AIDS Action Baltimore, Inc. at 14 East Eager Street, Baltimore, MD 21202 or 410-837-2437. Documents and information submitted to the State of Maryland under the Maryland Charitable Solicitations Act are available from the Office of the Secretary of State, State House, Annapolis, MD 21401 for the cost of copying and postage.

AIDS ACTION BALTIMORE, INC.
Statement of Financial Position
as at December 31, 2019 and 2018

ASSETS

<u>Current Assets</u>	2019	2018
Cash and Cash Equivalents	\$ 285,411	\$ 441,418
Contributions Receivable	57,642	83,277
Other Receivables	-0-	-0-
Prepaid Expenses	769	769
<u>TOTAL CURRENT ASSETS</u>	<u>\$ 343,822</u>	<u>\$525,464</u>
<u>Furniture & Equipment</u>		
Furniture and Equipment	\$ 59,032	\$ 59,032
Less: Accumulated Depreciation	58,599	57,674
<u>TOTAL FURNITURE & EQUIPMENT</u>	<u>433</u>	<u>1,358</u>
<u>OTHER ASSETS</u>		
Security Deposit	\$ 1,000	-0-
<u>TOTAL OTHER ASSETS</u>	<u>\$ 1,000</u>	<u>-0-</u>
<u>TOTAL ASSETS</u>	<u>\$ 345,255</u>	<u>\$ 526,822</u>
<u>LIABILITIES & NET ASSETS</u>		
<u>CURRENT LIABILITIES</u>		
Accrued Expense Payable	\$ 3,695	\$ 2,910
Credit Card Payable	20	-20-
Payroll Taxes Payable	807	-0-
<u>TOTAL CURRENT LIABILITIES</u>	<u>\$ 4,522</u>	<u>\$ 2,930</u>
<u>NET ASSETS</u>		
Unrestricted	\$ 331,649	\$ 522,005
Temporarily Restricted	9,084	1,887
<u>TOTAL NET ASSETS</u>	<u>\$ 340,733</u>	<u>\$ 523,892</u>
<u>TOTAL LIABILITIES & NET ASSETS</u>	<u>\$ 345,255</u>	<u>\$ 526,822</u>

AIDS ACTION BALTIMORE, INC.

Statement of Activities

For The Years Ended December 31, 2019 and 2018

	Temporarily Restricted	Un- Restricted	2019 Total	2018 Total
<u>PUBLIC SUPPORT AND REVENUE</u>				
<u>PUBLIC SUPPORT:</u>				
Contributions	\$ 17,830	\$ 24,865	\$ 42,695	\$ 64,470
Special Events	-0-	51,341	51,341	64,200
Grants-Education	-0-	155,561	155,561	360,182
Total Public Support	\$ 17,830	\$ 231,767	\$ 249,597	\$ 492,852
Net Assets Released from Restriction	-0-	-0-	-0-	-0-
<u>REVENUE:</u>				
Rental Income	-0-	-0-	-0-	-0-
Investment Income	-0-	63	63	53
<u>TOTAL SUPPORT AND REVENUE</u>	<u>\$ 17,830</u>	<u>\$ 231,830</u>	<u>\$ 249,660</u>	<u>\$ 492,914</u>
<u>EXPENSES</u>				
<u>Program Services:</u>				
Public Services	17,830	407,265	417,898	415,981
<u>SUPPORTING SERVICES</u>				
Management and General	-0-	14,921	14,921	15,541
<u>TOTAL EXPENSES</u>	<u>\$ 10,633</u>	<u>\$ 422,186</u>	<u>\$ 432,819</u>	<u>\$ 431,522</u>
Change in Net Assets	7,197	(190,356)	(183,159)	113,834
<u>NET ASSETS - BEGINNING OF THE YEAR</u>	<u>1,887</u>	<u>522,005</u>	<u>523,892</u>	<u>462,509</u>
<u>NET ASSETS - END OF THE YEAR</u>	<u>\$ 9,084</u>	<u>\$ 331,649</u>	<u>\$ 340,733</u>	<u>\$ 523,892</u>